Abstract:BACKGROUND Hepatocellular carcinoma (HCC) ranks sixth globally in cancer incidence and third in mortality rates. Unfortunately, over 70% of HCC patients forego the opportunity for curative surgery or liver transplantation due to inadequate physical examinations, poor physical condition, and limited organ availability upon diagnosis. Clinical guidelines endorse transarterial chemoembolization (TACE) as the frontline treatment for intermediate to advanced-stage HCC. Cryoablation (CRA) is an emerging local ablative therapy increasingly used in HCC management. Recent studies suggest that combining CRA with TACE offers complementary and synergistic effects, potentially improving long-term survival rates. However, the superiority of combined TACE + CRA therapy over TACE alone for HCC lesions equal to or exceeding 5 cm requires further investigation. AIM To compare the efficacy and safety of TACE combined with CRA vs TACE alone in the treatment of HCC with a diameter of ≥ 5 cm. METHODS PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and VIP databases were searched to retrieve all relevant studies on TACE and CRA up to July 2022. Meta-analysis was performed using RevMan 5.3 software. RESULTS After screening according to the inclusion and exclusion criteria, 6 articles were included, including 2 randomized controlled trials and 4 nonrandomized controlled trials, with a total of 575 patients included in the meta-analysis. The results showed that the objective response rate [odds ratio (OR) = 2.56, 95% confidence interval (CI):1.66-3.96, P < 0.0001), disease control rate (OR = 3.03, 95%CI: 1.88-4.89, P < 0.00001), 1-year survival rate (OR = 3.79, 95%CI: 2.50-5.76, P < 0.00001), 2-year survival rate (OR = 2.34, 95%CI: 1.43-3.85, P = 0.0008), and 3-year survival rate (OR = 3.34, 95%CI: 1.61-6.94, P = 0.001) were all superior to those of the control group; the postoperative decrease in alpha-fetoprotein value (OR = 295.53, 95%CI: 250.22-340.85, P < 0.0001), the postoperative increase in CD4 value (OR = 10.59, 95%CI: 8.78-12.40, P < 0.00001), and the postoperative decrease in CD8 value (OR = 6.47, 95%CI: 4.44-8.50, P < 0.00001) were also significantly higher than those in the TACE-alone treatment group. CONCLUSION Compared with TACE-alone treatment, TACE + CRA combined treatment not only improves the immune function of HCC patients with a diameter of ≥ 5 cm, but also enhances the therapeutic efficacy and long-term survival rate, without increasing the risk of complications. Therefore, TACE + CRA combined treatment may be a more recommended treatment for patients with HCC with a diameter of ≥ 5 cm.

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma.

Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma

Three-Dimensional Conformal Radiotherapy (3DCRT) Combined with Transcatheter Arterial Chemoembolization (TACE) for Inoperable or Unresectable Hepatocellular Carcinoma (HCC): Clinical Phase I/II Trial

Sequential Transcatheter Arterial Chemoembolization, Three-Dimensional Conformal Radiotherapy, and High-Intensity Focused Ultrasound Treatment for Unresectable Hepatocellular Carcinoma Patients

Three Dimentinal Radiotherapy Combined with Tanscatheter Arterial Chemoebolization Hyperthermia for Primary Liver Cancer

A Clinical Study of Transcatheter Arterial Chemoembolization Combined with Three-dimensional Conformal Radiotherapy in Liver Cancer

Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma

Efficacy and Safety of Intensity Modulated Radiation Therapy Following Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma

Comparison Between Chemoembolization Combined with Radiotherapy and Chemoembolization Alone for Large Hepatocellular Carcinoma

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma.

A Phase Ⅰ/Ⅱ Clinical Trial of Three Dimensional Conformal Radiation Therapy Combined with Transcatheter Arterial Chemoembolization for Liver Cancer

The Long-Term Efficacy of Combined Chemoembolization and Local Irradiation in the Treatment of Patients with Large Hepatocellular Carcinoma.

Clinical Application of a Combination Therapy of Percutaneous Radiofrequency and Transcatheter Arterial Chemoembolization in Large Hepatic Tumors

Combination of transcatheter arterial chemoembolization and radiofrequency ablation in hepatocellular carcinoma treatment

Three-dimensional Conformal Radiation Therapy and Intensity-Modulated Radiation Therapy Combined with Transcatheter Arterial Chemoembolization for Locally Advanced Hepatocellular Carcinoma: an Irradiation Dose Escalation Study.

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Delays Tumor Progression and Prolongs Overall Survival in Patients with Intermediate (BCLC B) Hepatocellular Carcinoma.

External-beam Radiotherapy after Transarterial Chemoembolization (TACE) Versus TACE Alone for Treatment of Inoperable HCC: A Randomized Phase III Trial

Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for ≥ 5 cm hepatocellular carcinoma

Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma